The FDA has approved a subcutaneous dose for initiation of lecanemab treatment in adults with Alzheimer’s disease, according to a press release from the administration.Previously, patients had to begin treatment with an intravenous dose.Researchers conducting a real-world study, presented at the Alzheimer’s Association International Conference, found that most patients remained stable over an average of 17 months on intravenous and…
Source: Healio News
